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Abstract
Background: Ventilator-associated pneumonia (VAP) which is an important part of all nosocomial
infections in intensive care unit (ICU) is a serious illness with substantial morbidity and mortality,
and increases costs of hospital care. We aimed to evaluate costs and risk factors for VAP in adult
ICU.
Methods: This is a-three year retrospective case-control study. The data were collected between
01 January 2000 and 31 December 2002. During the study period, 132 patients were diagnosed as
nosocomial pneumonia of 731 adult medical-surgical ICU patients. Of these only 37 VAP patients
were assessed, and multiple nosocomially infected patients were excluded from the study. Sixty
non-infected ICU patients were chosen as control patients.
Results: Median length of stay in ICU in patients with VAP and without were 8.0 (IQR: 6.5) and
2.5 (IQR: 2.0) days respectively (P < 0.0001). Respiratory failure (OR, 11.8; 95%, CI, 2.2–62.5; P <
0.004), coma in admission (Glasgow coma scale < 9) (OR, 17.2; 95% CI, 2.7–107.7; P < 0.002),
depressed consciousness (OR, 8.8; 95% CI, 2.9–62.5; P < 0.02), enteral feeding (OR, 5.3; 95% CI,
1.0–27.3; P = 0.044) and length of stay (OR, 1.3; 95% CI, 1.0–1.7; P < 0.04) were found as important
risk factors. Most commonly isolated microorganism was methicillin resistant Staphylococcus
aureus (30.4%). Mortality rates were higher in patients with VAP (70.3%) than the control patients
(35.5%) (P < 0.003). Mean cost of patients with and without VAP were 2832.2+/-1329.0 and 868.5+/
-428.0 US Dollars respectively (P < 0.0001).
Conclusion: Respiratory failure, coma, depressed consciousness, enteral feeding and length of
stay are independent risk factors for developing VAP. The cost of VAP is approximately five-fold
higher than non-infected patients.
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Nosocomial pneumonia (NP) which is an important part
of all nosocomial infections in intensive care unit (ICU) is
a serious illness with substantial morbidity and mortality,
and increases costs of hospital care [1-3]. The term of
nosocomial pneumonia (hospital-acquired pneumonia)
broadly covers all infections occurring after the first 48
hours of the hospital admission excluding any infection
incubations in this period. Intensive care unit acquired
pneumonia (occurring after the first 48 hours of admis-
sion to the ICU) and ventilator-associated pneumonia
(VAP; occurring after the first 48 hours of starting mechan-
ical ventilation) are also included in the broader term
"nosocomial pneumonia" [4]. Risk factors for VAP
include mechanical ventilation for > 48 hours, stay in an
ICU, duration of ICU or hospital stay, severity of underly-
ing illness, and presence of co morbidities. Pseudomonas
aeruginosa, Staphylococcus aureus, and Enterobacter are the
most common causes of NP [5]. The greatest number of
reports on NP in ICUs is published from USA, and reports
from Turkey are scarce. The importance of international
comparisons of results of infection surveillance data for
prevention of nosocomial infection and reaching a quality
of care is stressed [6]. This is the first cost analysis and risk
factor study on VAP in ICU from a developing country,
Turkey.
Methods
This retrospective case control study was performed
between 01 January 2000 and 31 December 2002 in the
Anaesthesiology Intensive Care Unit in Pamukkale Uni-
versity Hospital, Denizli, Turkey.
The three years data collected in this study consisted of 97
(37 intubated patients with VAP and 60 controls) adult
ICU patients. Multiple nosocomial infections including
pneumonia and NP in non-intubated patients were
excluded from the study because we aimed to detect inde-
pendent risk factors and the costs, for only VAP. Sixty
mechanically ventilated control cases that stayed in the
ICU for more than 48 hours and did not develop any
nosocomial infection were chosen with respect to similar-
ity of age (+/- 2 years), gender, and underlying disease
with the VAP group.
The central medical-surgical adult ICU was a six-bed unit
staffed by four physicians and twelve nurses. Haematolog-
ical and biochemical tests (daily), chest radiographs (2–4
times in a week) and microbiological cultures from blood,
nasopharynx, tracheal aspirate, urine and wounds (on
admission and twice a week) were performed routinely.
An infectious diseases physician consultated the patients
daily. An infection control nurse collected data daily on
standard surveillance charts. The decision of VAP or colo-
nisation was made according to the laboratory and clini-
cal findings. Appropriate antimicrobial therapy was given
to the patients when necessary. Education on infection
control procedures is performed twice in a year for all ICU
staff. Infection control measures and guidelines on pre-
vention of nosocomial infections are applied according to
CDC [7].
All data including gender, age, admission and discharge
date, admission diagnosis and the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score at
patient's admission to the ICU were recorded. The other
data consisting of the usage of H2 receptor antagonist,
mechanical ventilation, nasogastric tubing, blood transfu-
sion, central venous catheterisation, urinary catheterisa-
tion, tracheotomy, surgical drains, malignancy, trauma,
diabetes mellitus, renal failure (serum-creatinine ≥ 200
mol/l), respiratory failure (PaCO2 > 49 mm Hg and/or
PaO2 < 50–60 mmHg), central nervous system disease,
coma (GCS = Glasgow coma scale < 9), depressed con-
sciousness, intoxication, surgical operations, infection on
admission, infection sites, isolated microorganisms and
their susceptibility patterns and mortality were also
recorded. All these factors were investigated as possible
risk factors for VAP.
Criteria for defining VAP were those recommended by the
CDC [7]. A diagnosis of VAP was considered when radio-
logical evidence of new and persistent (> 48 hrs) pulmo-
nary infiltrates were detected together with at least two of
the following features: temperature higher than 38°C and
lower than 35°C, peripheral leukocytosis, (5000 per mm3
or a 25% increase in the circulating leukocytes from base-
line), or leukocyte recount lower than 4000 per mm3
purulent respiratory secretions, and appearance or wors-
ening of respiratory insufficiency. Moreover, the presence
of significant growth on quantitative cultures of the bron-
choscopic protected specimen brush (≥ 103 colony form-
ing units (cfu)/ml) was required to accept the pneumonia
as microbiologically proven [8]. Patients were followed
daily until discharge from the ICU or to death. Risk of
mortality for each group based on their APACHE II scores
was analysed.
Statistical analysis
Statistical analysis was performed in two steps using SPSS
10.0 (SPSS Inc., Chicago, USA). First, categorical variables
such as possible risk factors for VAP were assessed with
bivariate analyses (Pearson correlation). Second, all of the
risk factors, which were found significant with bivariate
analysis, were included in a model, and multivariate logis-
tic regression analysis was done. All P-value less than 0.05
were considered significant.Page 2 of 7
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From a total of 731 ICU patients 132 of them were diag-
nosed as NP during the study period. Of these only 37
intubated patients with VAP were included in the study.
Multiple nosocomial infections including pneumonia (n
= 92) or non-intubated patients with NP (n = 3) were
excluded from the study. The ages of the patients were
between 20 and 74 (Table 1). The incidence rate of VAP
was 8.9 in 1000-patient days. The duration of ventilation
before diagnosis of VAP was found as 4.0 days.
Table 1: Characteristics and admission diagnosis of patients
VAP Group (n = 37) Control Group (n = 60) P- value
Characteristic median (IQR) median (IQR)
Age (years) 56.0 (25.0) 56.5 (14.8) NS
APACHE II score 23.0 (7.0) 14.0 (10.0) <0.0001
Length of stay in ICU (days) 8.0 (6.5) 2.5 (2.0) <0.0001
Admission diagnosis No of patients (%) No of patients (%)
Trauma 8 (21.6 %) 7 (11.7 %)
Pulmonary disease 7 (18.9 %) 9 (15.0 %)
CNS disease 7 (18.9 %) 8 (13.3 %)
Renal insufficiency 2 (5.4 %) 5 (8.3 %)
CVS disease 3 (8.1 %) 6 (10.0 %)
Infectious disease 3 (8.1 %) 2 (3.3 %)
Intoxication 3 (8.1 %) 6 (10.0 %)
Malignancy 1 (2.7 %) 7 (11.7 %)
Others 3 (8.1 %) 10 (16.7 %)
Values are expressed as median, IQR (Interquartile Range). Abbreviations: VAP: ventilator-associated pneumonia; APACHE II score: the Acute 
Physiology and Chronic Health Evaluation II score, NS: non-significant, CNS: central nervous system, CVS: cardiovascular system.
Table 2: Bivariate and multivariate analyses of risk factors for VAP (mean ± SD)
Bivariate analysis Multivariate analysis
Risk factors VAP Group Control Group OR (95% CI) P-value OR (95% CI) P-value
Respiratory failure 34 (91.9 %) 12 (20.0 %) 45.3 (11.8–
173.0)
<0.0001 11.8 (2.2–62.5) 0.004
Coma (GCS < 9) 23 (62.2 %) 3 (5.0 %) 31.2 (8.2–118.9) <0.0001 17.2(2.7–107.7) 0.002
Depressed consciousness 25 (67.6 %) 12 (20.0 %) 29.4 (10.9–58.7) <0.0001 8.8 (2.9–62.5) 0.02
Enteral feeding 30 (81.1 %) 14 (23.3 %) 14.1 (5.1–38.9) <0.0001 5.3 (1.0–27.3) 0.044
Length of stay 9.4 ± 7.1 3.5 ± 2.3 <0.0001 1.3 (1.0–1.7) 0.023
APACHE II scores 22.9 ± 5.2 15.3 ± 7.0 <0.0001 -- NS
Nasogastric tubing 28 (75.7 %) 21 (35.0 %) 5.8 (2.3–14.5) 0.001 -- NS
CVC 32 (86.5 %) 41 (68.3 %) 3.0 1.0–7.3) 0.044 -- NS
Diabetes mellitus 5 (13.5 %) 2 (3.3 %) 4.5 (0.8–24.7) NS
Trauma 1 (2.7 %) 2 (3.3 %) 0.8 (0.1–9.2) NS
Blood transfusion 14 (37.8 %) 21 (35.0 %) 1.1 (0.4–2.6) NS
TPN 9 (24.3 %) 15 (25.0 %) 1.0 (0.4–2.5) NS
Corticosteroids 2 (5.4 %) 5 (8.3 %) 0.6 (0.1–3.4) NS
H2 receptor antagonists 37 (100.0 %) 58 (96.7 %) - NS
Urinary catheterization 37 (100.0 %) 57 (95.0 %) -- NS
PVC 30 (81.1 %) 45 (75.0 %) 1.4 (0.6–3.9) NS
Surgical drains 8 (21.6 %) 11 (18.3 %) 1.2 (0.4–3.4) NS
Tracheostomy 2 (5.4 %) 1 (1.7 %) 3.3 (0.3–38.6) NS
Arterial cannulation 3 (8.1 %) -- -- NS
Values are expressed as mean ± SD and number of patients (%). Possible risk factors for VAP were assessed with bivariate analysis. All of the risk 
factors which were found significant with bivariate analysis were included in a model, and multiple logistic regression analysis was done. 
Abbreviations: OR: odds ratio, CI: confidence interval, PVC: peripheral venous catheter, CVC: central venous catheterization, TPN: total parenteral 
nutrition.Page 3 of 7
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ing the length of stay in ICU and APACHE II scores are
shown in Table 1. Significant possible risk factors for VAP
are shown in Table 2. Multiple logistic regression analysis
revealed that respiratory failure, coma in admission (Glas-
gow coma scale < 9), depressed consciousness, enteral
feeding and length of stay were significant risk factors for
VAP in ICU with (Table 2).
The most frequently isolated microorganisms were methi-
cillin resistant Staphylococcus aureus (30.4%), Pseudomonas
aeruginosa (21.4%), Acinetobacter spp. (12.5%) and Kleb-
siella pneumoniae (10.7%). In early onset pneumonias
MRSA, MR-KNS, E. coli and K. pneumoniae, in late onset
pneumonias P. aeruginosa, Acinetobacter spp. and MRSA
were the predominant isolated pathogens in this study.
Early onset pneumonia was described as pneumonia
occurring in the first three to five days after admission to
the hospital.
Median costs of patients with VAP and without VAP were
2839.3 (IQR: 1585.6) and 653.4 (IQR: 825.2) US Dollars
respectively (P < 0.0001). Distribution of costs is shown
in Table 3.
Crude mortality rates were higher in patients with VAP
(70.3%) than the control patients (35.0%) (P < 0.002).
Mortality rate due to organ failures was found as 46.2%.
Mortality for each group based on their APACHE II scores
is shown in Table 4.
Discussion
Although patients in ICU are a small subgroup of all hos-
pitalised patients they account for approximately 25% of
all nosocomial infections. The incidence of nosocomial
infections in ICU is high due to underlying disease, sever-
ity of illness, type of ICU, length of stay and invasive
devices used. Nosocomial pneumonia is the leading cause
of death from hospital-acquired infections [9,10].
Table 3: Costs of therapeutic interventions in the ICU (US Dollars)
VAP group (n = 37) Control group (n = 60)
Median(IQR) Mean (± SD) Median (IQR) Mean (± SD) P-value
ICU bed cost 190.8 (166.4) 230.2 ± 120.2 92.4 (78.6) 113.5 ± 72.2 <0.0001
Antibiotics 589.6 (378.3) 576.7 ± 362.4 98.9 (141.1) 219.2 ± 458.2 <0.002
Laboratory 400.6 (264.5) 435.0 ± 273.4 106.8 (127.3) 112 ± 134.2 <0.0001
Other drugs 218.3 (587.8) 497.4 ± 553.5 135.8 (229.5) 204.3 ± 288.4 0.032
Mechanical ventilation 90.8 (68.5) 108.9 ± 51.2 0.0 11.9 ± 23.6 <0.0001
Respiratory circuit. filters 60.5 (36.6) 59.7 ± 36.4 0.0 10.7 ± 21.5 <0.0001
Tracheal aspiration 298.9 (146.8) 321.9 ± 159.8 0.0 21.7 ± 40.8 <0.0001
IV infusion sets 84.6 (64.1) 97.3 ± 37.9 33.7 (13.5) 40.2 ± 23.7 <0.0001
CVC 26.1 (0.4) 29.9 ± 11.6 26.1 (0.0) 21.3 ± 11.3 0.021
Enteral nutritional products 113.1 (163.7) 137.3 ± 211.5 0.0 (0.0) 13.0 ± 37.4 0.002
Parenteral nutritional products 0.0 (82.2) 76.1 ± 111.5 0.0 (0.0) 12.9 ± 42.2 0.008
Urinary catheters 5.3 (1.4) 6.4 ± 3.4 5.3 (0.0) 5.0 ± 1.5 0.028
Monitorization 114.8 (81.5) 131.3 ± 54.6 32.6 (32.6) 49.9 ± 27.4 <0.0001
Wound dressing 26.6 (23.2) 38.8 ± 17.5 9.3 (7.1) 11.6 ± 8.4 <0.0001
Blood transfusion 0.0 (116.3) 90.3 ± 177.1 0.0 (0.0) 21.3 ± 51.9 0.038
Total 2839.3 (1585.6) 2832.2 ± 1329.0 653.4 (825.2) 868.5 ± 428.0 <0.0001
Values are expressed as median, IQR (interquartile range) and mean ± SD (standard deviation).
Table 4: Mortality rates based on APACHE II scores
Bivariate analysis Multivariate analysis
Death Discharged OR (95% CI) P-value OR (95% CI) P-value
VAP Group 26 (70.3) 11 (29.7) 4.4 (1.8–10.6) 0.002 -- NS
Control Group 21 (35.0) 39 (65.0) -- -- NS
APACHE II
< 10 3 (13.0) 20 (87.0) -- <0.0001 --
11–20 15 (40.5) 22 (59.5) 4.5 (1.1–18.0) 4.5 (1.1–18.0) 0.032
> 20 29 (78.4) 8 (21.6) 24.1 (5.7–102.3) 24.1 (5.7–102.3) <0.0001
Total 47 (48.5) 50 (51.5)Page 4 of 7
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tion [11] similar to the published studies from other
countries [1,3,12,13]. The estimated prevalence of NP
within the hospital settings ranges from 10% to 65%, with
case fatality rates which is greater than 25% in most stud-
ies [14]. The incidence of VAP in ICU which are reported
as 15.5% [15] and 9.3% [16].
Recent investigations also suggest that NP has become the
most common nosocomial infection among critically ill
patients [1,17]. Despite abundant literature on the man-
agement of NP, a number of aspects, from diagnosis to the
therapy, are still controversial [18].
Respiratory failure, length of stay, coma (GCS < 9) in
admission, depressed consciousness, enteral feeding and
length of stay were found significant independent risk fac-
tors by using multivariate analysis in our patients with
VAP. Although risk factors for the development of NP in
ICU patients have been assessed in multiple studies,
results are frequently controversial mainly due to method-
ological differences. However, mechanical ventilation, H2
receptor blocker usage, prophylactic antimicrobial ther-
apy, depressed consciousness, massive gastric aspiration
[19-23], length of stay in ICU, duration of mechanical
ventilation, trauma, severity of illness and underlying dis-
ease, male gender [16,24], transfer from another hospital
ward, a colonized central venous catheter [25], unplanned
extubation, reintubation after weaning [26], supine body
position, enteral nutrition, Glasgow coma scale score of
less than 9 [8] are reported as independent risk factors for
developing NP in ICU patients. Our results are generally
in accordance with these studies but we did not find H2
receptor blockers as independent risk factor for NP. This
might be due to almost all the patients received the drugs
for stress ulcer prophylaxis.
In this study, the most frequently isolated microorgan-
isms were methicillin resistant Staphylococcus aureus
(30.4%), Pseudomonas aeruginosa (21.4%) and Acineto-
bacter spp. (12.5%). This is in accordance with different
studies where Staphylococcus aureus, Pseudomonas aerugi-
nosa, Acinetobacter spp. and Enterobacter spp. were isolated
from ICU patients with NP [14,19,28,29].
In our study, crude mortality rates were higher in patients
with VAP (70.3%) compared to control patients (35.5%).
The risk of death based on three scale APACHE II scores
was calculated in two groups. APACHE II scores and VAP
contribute the mortality in bivariate analysis but in multi-
variate analysis only APACHE II scores were significant
(Table 4). Tejada Artigas et al. [19] found the mortality
rates for patients with and without NP were 43.5% and
18.8% respectively. Georges et al. [30] reported that the
mortality rate increased from 33.3% to 54.3% after diag-
nosis of NP in their patients. Different methodologies
including case control or cohort studies with multivariate
analysis were used in order to determine mortality rate of
NP. Whatever the method used, results are very heteroge-
neous and highly controversial. Even if the methodology
of those studies is most often appropriate, results remain
extremely confusing and raise more questions than pro-
vide answers. For example, the mortality rates of control
patients range from 5% to 39%, and the mortality rates of
patients with VAP range from 24% to 58% in the studies.
Thus, the attributable mortality is influenced by the global
strategy used to diagnose and manage NP, which varies
considerably from one country to another [31,32].
Extra costs of nosocomial infections include; bed, ICU
stay, haematological, biochemical, microbiological and
radiological tests, antibiotics, other drugs, extra surgical
procedures and working hours. Drug and especially
antibiotic acquisition in addition to increased length of
stay are the widely used and well-described parameters in
calculating cost. Litigation, mortality and morbidity and
some other parameters are not very well described in cal-
culating costs in nosocomial infections [33,34]. Therefore
the impact of mortality on the calculations of cost is diffi-
cult to interpret. Ventilator-associated pneumonia adds
significant costs to individual hospitalisations. Centres for
Disease Control [35] estimated that an episode of NP
added 5.9 days to the average hospital stay and $5683 in
excess costs. Other estimates put the excess hospital costs
associated with NP at $4947 per episode of NP [36].
Boyce and colleagues [37] also reported that, among 31 of
33 Medicare patients who developed NP, hospital costs
for the entire admission exceeded reimbursements, with a
net loss of $5800 per case. Dietrich et al. [38] reported an
excess cost amounted to 14606 DM in patients with NP.
Warren et al. [15] reported that patients with VAP had sig-
nificantly higher hospital costs than uninfected patients
($70,568 vs. $21,620), and estimated the attributable cost
of VAP to be $11,897). Total ICU expenditure was
$2832.2 ± 1329.0 USD for VAP group and $868.5 ± 428.0
for the control group in our study.
Economic analysis of patients with VAP in ICU showed
that a group of invasive devices and procedures including
central venous catheters, respiratory circuit and filters, uri-
nary catheters, intravenous infusion catheters, enteral or
parenteral nutritional products, aspiration and monitori-
zation is accounted the most important part of the cost
followed by antibiotics and laboratory investigations
(Table 3). In the assessment of costs, our results are con-
sistent with a marked excess cost of VAP, but when com-
pared with the other studies from Europe and North
America our ICU bed prices and procedure costs are lower
in our country [35-38]. Besides, as a developing country in
Turkey, extremely low fee of ICU bed and procedures [39],Page 5 of 7
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BMC Pulmonary Medicine 2004, 4 http://www.biomedcentral.com/1471-2466/4/3the magnitude of the hospital may affect the costs from
the point of realized medical processes. We think that the
most important data is the cost of VAP, and it is approxi-
mately five-fold higher than control patients.
In conclusion, respiratory failure, coma (GCS < 9) in
admission, depressed consciousness, enteral feeding and
length of stay are independent risk factors for developing
VAP in our ICU. High mortality rates and costs of VAP sug-
gest that infection control activities which are aimed to
prevent VAP in ICU must be constantly maintained in
order to improve the quality of care.
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